Tetraphase Pharmaceuticals Inc (TTPH) Expected to Announce Earnings of -$0.56 Per Share
Equities analysts predict that Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) will report ($0.56) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Tetraphase Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.61) and the highest is ($0.49). Tetraphase Pharmaceuticals posted earnings of ($0.58) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 3.4%. The firm is expected to report its next earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that Tetraphase Pharmaceuticals will report full-year earnings of ($2.54) per share for the current year, with EPS estimates ranging from ($2.64) to ($2.45). For the next year, analysts forecast that the company will post earnings of ($1.83) per share, with EPS estimates ranging from ($2.03) to ($1.61). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Tetraphase Pharmaceuticals.
Tetraphase Pharmaceuticals (NASDAQ:TTPH) last issued its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by $0.07. Tetraphase Pharmaceuticals had a negative return on equity of 112.91% and a negative net margin of 2,005.74%. The firm had revenue of $1.59 million during the quarter, compared to analyst estimates of $1.54 million. During the same quarter in the prior year, the firm earned ($0.47) EPS. The business’s quarterly revenue was up 28.2% compared to the same quarter last year.
A number of research firms recently issued reports on TTPH. BMO Capital Markets reiterated a “buy” rating and issued a $12.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Monday, May 15th. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, July 6th. ValuEngine lowered shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Thursday, July 27th. Finally, Stifel Nicolaus raised shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and increased their price target for the company from $8.00 to $15.00 in a report on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the stock. Tetraphase Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $11.21.
COPYRIGHT VIOLATION WARNING: This news story was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was copied illegally and reposted in violation of United States and international trademark and copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/10/tetraphase-pharmaceuticals-inc-ttph-expected-to-announce-earnings-of-0-56-per-share.html.
Shares of Tetraphase Pharmaceuticals (NASDAQ TTPH) traded up 3.15% during trading on Friday, reaching $6.88. 534,344 shares of the company’s stock were exchanged. The company has a 50 day moving average of $6.36 and a 200 day moving average of $7.21. The firm’s market capitalization is $351.24 million. Tetraphase Pharmaceuticals has a 52-week low of $3.11 and a 52-week high of $9.93.
In other Tetraphase Pharmaceuticals news, insider Jacques Dumas sold 17,500 shares of the stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total value of $105,000.00. Following the completion of the sale, the insider now directly owns 17,500 shares of the company’s stock, valued at approximately $105,000. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 5.50% of the stock is owned by corporate insiders.
Several large investors have recently added to or reduced their stakes in the company. UBS Group AG lifted its holdings in shares of Tetraphase Pharmaceuticals by 2.3% during the 1st quarter. UBS Group AG now owns 17,269 shares of the biopharmaceutical company’s stock worth $159,000 after acquiring an additional 387 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Tetraphase Pharmaceuticals by 0.7% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 129,681 shares of the biopharmaceutical company’s stock worth $925,000 after acquiring an additional 874 shares during the period. Teza Capital Management LLC lifted its holdings in shares of Tetraphase Pharmaceuticals by 8.9% during the 1st quarter. Teza Capital Management LLC now owns 15,650 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 1,281 shares during the period. American International Group Inc. lifted its holdings in shares of Tetraphase Pharmaceuticals by 7.1% during the 1st quarter. American International Group Inc. now owns 22,390 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 1,486 shares during the period. Finally, Citadel Advisors LLC lifted its holdings in shares of Tetraphase Pharmaceuticals by 18.6% during the 1st quarter. Citadel Advisors LLC now owns 15,924 shares of the biopharmaceutical company’s stock worth $146,000 after acquiring an additional 2,496 shares during the period. 41.73% of the stock is owned by institutional investors.
About Tetraphase Pharmaceuticals
Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tetraphase Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.